View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
May 28, 2020

Roche’s Tecentriq gains first-line approval in NSCLC but Merck’s Keytruda dominates the space

By Victoria Smith

Earlier this month, Roche’s Tecentriq (atezolizumab) gained FDA approval as first-line monotherapy to treat metastatic non-small cell lung cancer (NSCLC), becoming the fourth approval in the indication, as well as the fifth approval in lung cancer as a whole.

The approval comes from data of the Phase III Impower110 trial, which concluded an overall survival benefit in patients with high PD-L1 expression. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena